OM - Outset Medical Inc Stock Price, Fair Value and News

2.55USD+0.09 (+3.66%)Market Closed

Market Summary

USD2.55+0.09

Market Closed

3.66%

OM Stock Price

View Fullscreen

OM RSI Chart

OM Valuation

Market Cap

128.8M

Price/Earnings (Trailing)

-0.75

Price/Sales (Trailing)

0.99

EV/EBITDA

-1.24

Price/Free Cashflow

-0.96

OM Price/Sales (Trailing)

OM Profitability

EBT Margin

-132.14%

Return on Equity

-140.62%

Return on Assets

-55.07%

Free Cashflow Yield

-104.68%

OM Fundamentals

OM Revenue

Revenue (TTM)

130.4M

Rev. Growth (Yr)

-4.69%

Rev. Growth (Qtr)

0.48%

OM Earnings

Earnings (TTM)

-172.8M

Earnings Growth (Yr)

6.86%

Earnings Growth (Qtr)

16.41%

Breaking Down OM Revenue

Last 7 days

18.3%

Last 30 days

23.6%

Last 90 days

-25.9%

Trailing 12 Months

-86.1%

How does OM drawdown profile look like?

OM Financial Health

Current Ratio

5.26

Debt/Equity

1.06

Debt/Cashflow

-1.01

OM Investor Care

Shares Dilution (1Y)

3.84%

Diluted EPS (TTM)

-3.49

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	118.3M	129.3M	131.9M	130.4M
2022	110.2M	110.1M	111.5M	115.4M
2021	65.7M	79.1M	91.7M	102.6M
2020	19.8M	28.6M	39.8M	49.9M
2019	5.3M	8.5M	11.8M	15.1M
2018	0	0	0	2.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Outset Medical Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 15, 2024	nash marc	sold	-5,092	2.13	-2,391	svp operations and r&d
Mar 12, 2024	lang brent d.	acquired	-	-	108,024	-
Mar 01, 2024	ahmed nabeel	sold	-4,989	3.15	-1,584	chief financial officer
Feb 29, 2024	ahmed nabeel	acquired	4,245	2.68	1,584	chief financial officer
Feb 23, 2024	trigg leslie	acquired	-	-	131,687	chair and ceo
Feb 23, 2024	ahmed nabeel	sold (taxes)	-39,577	3.72	-10,639	chief financial officer
Feb 23, 2024	trigg leslie	sold (taxes)	-169,401	3.72	-45,538	chair and ceo
Feb 23, 2024	ahmed nabeel	acquired	-	-	20,922	chief financial officer
Feb 15, 2024	trigg leslie	sold	-18,992	3.57	-5,320	chair and ceo
Feb 15, 2024	brottem john l.	sold	-11,927	3.57	-3,341	general counsel

Which funds bought or sold OM recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	AMALGAMATED BANK	reduced	-76.27	-34,000	4,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	-148,303	146,676	-%
Apr 19, 2024	Valeo Financial Advisors, LLC	sold off	-100	-117,143	-	-%
Apr 19, 2024	Kovack Advisors, Inc.	sold off	-100	-62,350	-	-%
Apr 18, 2024	Allspring Global Investments Holdings, LLC	sold off	-100	-9,083	-	-%
Apr 17, 2024	GRIFFIN ASSET MANAGEMENT, INC.	added	5.72	-283,673	217,369	0.03%
Apr 09, 2024	Rise Advisors, LLC	unchanged	-	-79.00	56.00	-%
Apr 09, 2024	ADIRONDACK TRUST CO	unchanged	-	-261	621	-%
Apr 05, 2024	CWM, LLC	new	-	-	-	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	new	-	1,440	1,440	-%

Are Funds Buying or Selling OM?

Are funds buying OM calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own OM

No. of Funds

Unveiling Outset Medical Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 10, 2024	ameriprise financial inc	10.12%	5,112,408	SC 13G/A
Feb 14, 2024	t. rowe price investment management, inc.	6.3%	3,166,747	SC 13G
Feb 14, 2024	ameriprise financial inc	5.94%	2,982,490	SC 13G
Feb 13, 2024	bellevue group ag	1.1%	1,760,134	SC 13G/A
Feb 13, 2024	vanguard group inc	7.85%	3,941,367	SC 13G/A
Feb 09, 2024	morgan stanley	6.8%	3,413,343	SC 13G
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 26, 2024	blackrock inc.	7.6%	3,795,419	SC 13G/A
Jan 23, 2024	jpmorgan chase & co	9.4%	4,745,757	SC 13G/A
Sep 08, 2023	jpmorgan chase & co	10.0%	5,008,104	SC 13G/A

Recent SEC filings of Outset Medical Inc

View All Filings

Date Filed	Form Type	Document
Apr 11, 2024	DEF 14A	DEF 14A
Apr 11, 2024	DEFA14A	DEFA14A
Apr 10, 2024	SC 13G/A	Major Ownership Report
Mar 15, 2024	144	Notice of Insider Sale Intent
Mar 15, 2024	4	Insider Trading
Mar 13, 2024	3	Insider Trading
Mar 13, 2024	4	Insider Trading
Mar 13, 2024	8-K	Current Report
Mar 04, 2024	4	Insider Trading
Mar 01, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Outset Medical Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	185.5B	40.1B	-2.69%	-2.54%	32.41	4.63	-8.12%	-17.45%
BDX	67.5B	19.5B	-4.86%	-10.59%	53.77	3.46	4.02%	-22.04%
ALGN	23.6B	3.9B	-2.36%	-14.10%	52.95	6.1	3.42%	23.09%
BAX	20.8B	14.8B	-2.22%	-9.67%	7.83	1.4	2.12%	209.17%
MID-CAP
HSIC	9.4B	12.3B	-0.49%	-14.47%	22.62	0.76	-2.44%	-22.68%
ATR	9.3B	3.5B	-1.02%	16.40%	32.52	2.65	4.97%	18.89%
BIO	8.1B	2.7B	-18.63%	-38.25%	-12.74	3.04	-4.68%	82.43%
XRAY	6.4B	4.0B	-5.77%	-25.53%	-47.67	1.62	1.10%	85.84%
AXNX	3.4B	366.4M	-2.62%	10.65%	-558.61	9.25	33.86%	89.83%
PDCO	2.3B	6.6B	-4.73%	-4.84%	12.02	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-11.22%	-19.13%	-1.92	0.41	7.73%	-1066.14%
ANIK	383.0M	166.7M	1.30%	-3.37%	-4.63	2.3	6.67%	-456.34%
ANGO	241.5M	324.0M	12.50%	-31.24%	-1.26	0.75	-3.19%	-337.41%
APYX	45.7M	52.3M	5.60%	-56.15%	-2.44	0.87	17.61%	19.28%
AEMD	4.0M	3.7M	-11.70%	184.91%	-0.32	1.06	5.77%	8.23%

Outset Medical Inc News

Latest updates

Outset Medical Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	0.5%	30,507,000	30,362,000	36,040,000	33,467,000	32,007,000	27,761,000	25,057,000	30,550,000	28,152,000	26,318,000	25,216,000	22,916,000	17,247,000	13,756,000	11,742,000	7,190,000	7,085,000	2,630,000	2,872,000	2,491,000	-
Gross Profit	7.8%	7,712,000	7,157,000	7,703,000	6,428,000	5,273,000	4,336,000	3,782,000	4,442,000	3,321,000	2,946,000	1,052,000	289,000	417,000	-5,126,000	-4,764,000	-3,564,000	-2,780,000	-5,294,000	-4,470,000	-5,258,000	-
Operating Expenses	-14.3%	45,065,000	52,611,000	51,181,000	49,913,000	45,097,000	45,335,000	47,503,000	40,917,000	44,120,000	33,084,000	30,958,000	29,965,000	32,032,000	35,607,000	20,145,000	16,646,000	-	13,156,000	-	-	-
S&GA Expenses	-10.2%	22,194,000	24,720,000	24,985,000	24,333,000	23,631,000	22,276,000	23,198,000	20,377,000	22,991,000	15,726,000	13,204,000	13,149,000	15,198,000	13,344,000	9,244,000	7,282,000	-	5,009,000	-	-	-
R&D Expenses	-22.0%	12,532,000	16,076,000	14,906,000	13,793,000	11,444,000	13,059,000	13,521,000	10,831,000	11,410,000	9,729,000	8,032,000	7,570,000	7,784,000	9,175,000	6,053,000	5,838,000	-	5,708,000	-	-	-
EBITDA Margin	1.7%	-1.18	-1.20	-1.20	-1.34	-1.33	-1.39	-1.32	-1.19	-1.22	-1.26	-1.61	-	-	-	-	-	-	-	-	-	-
Interest Expenses	6.3%	3,417,000	3,213,000	3,103,000	2,942,000	2,096,000	567,000	481,000	422,000	431,000	431,000	431,000	422,000	430,000	428,000	1,032,000	1,001,000	-	1,047,000	-	-	-
Income Taxes	30.2%	112,000	86,000	133,000	192,000	64,000	20,000	96,000	115,000	125,000	-	35,000	39,000	-	-	-	-	-	20,000	-	-	-
Earnings Before Taxes	16.5%	-38,488,000	-46,094,000	-43,913,000	-43,779,000	-41,380,000	-40,761,000	-43,743,000	-36,777,000	-41,107,000	-30,470,000	-30,173,000	-29,986,000	-32,043,000	-42,294,000	-26,505,000	-20,650,000	-	-15,382,000	-	-	-
EBT Margin	0.5%	-1.32	-1.33	-1.31	-1.43	-1.41	-1.46	-1.38	-1.26	-1.28	-1.34	-1.70	-	-	-	-	-	-	-	-	-	-
Net Income	16.4%	-38,600,000	-46,180,000	-44,046,000	-43,971,000	-41,444,000	-40,781,000	-43,839,000	-36,892,000	-41,232,000	-30,470,000	-30,208,000	-30,025,000	-32,043,000	-42,294,000	-26,505,000	-20,650,000	-19,446,000	-15,402,000	-17,029,000	-16,422,000	-
Net Income Margin	0.5%	-1.33	-1.33	-1.32	-1.44	-1.41	-1.46	-1.38	-1.26	-1.29	-1.34	-1.70	-	-	-	-	-	-	-	-	-	-
Free Cashflow	26.7%	-25,495,000	-34,781,000	-28,971,000	-45,566,000	-36,616,000	-37,053,000	-40,572,000	-39,813,000	-33,527,000	-28,622,000	-31,688,000	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																		(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2018Q4
Assets	2.0%	314	308	334	363	400	366	401	432	463	489	505	380	404	426	313	201	88.00	151
Current Assets	2.6%	291	284	309	337	374	310	346	377	410	433	448	322	346	368	-	-	80.00	148
Cash Equivalents	88.7%	69.00	36.00	36.00	36.00	73.00	64.00	75.00	114	182	231	274	252	295	311	142	158	37.00	33.00
Inventory	2.0%	49.00	48.00	44.00	48.00	51.00	55.00	54.00	43.00	39.00	34.00	29.00	25.00	18.00	12.00	-	-	5.00	3.00
Net PPE	-3.6%	13.00	14.00	15.00	15.00	16.00	16.00	15.00	14.00	13.00	15.00	15.00	16.00	15.00	14.00	-	-	8.00	2.00
Liabilities	22.8%	191	155	151	146	154	87.00	91.00	86.00	89.00	79.00	74.00	73.00	75.00	72.00	65.00	58.00	51.00	47.00
Current Liabilities	4.3%	55.00	53.00	49.00	44.00	52.00	50.00	55.00	49.00	52.00	41.00	35.00	35.00	37.00	33.00	-	-	25.00	10.00
Long Term Debt	34.4%	130	97.00	97.00	96.00	96.00	30.00	29.00	30.00	30.00	30.00	30.00	30.00	30.00	30.00	-	-	22.00	28.00
LT Debt, Current	-	-	-	-	-	-	-	1.00	-	-	-	-	-	-	-	-	-	8.00	-
LT Debt, Non Current	34.4%	130	97.00	97.00	96.00	96.00	30.00	29.00	30.00	30.00	30.00	30.00	30.00	30.00	30.00	-	-	22.00	28.00
Shareholder's Equity	-19.2%	123	152	183	216	246	279	310	345	374	410	431	307	329	354	-	-	-	-
Retained Earnings	-4.2%	-961	-923	-876	-832	-788	-747	-706	-662	-625	-584	-554	-524	-494	-462	-	-	-372	-287
Additional Paid-In Capital	0.8%	1,085	1,075	1,060	1,049	1,035	1,027	1,017	1,009	1,000	994	985	831	823	816	-	-	0.00	-
Shares Outstanding	0.3%	50.00	50.00	50.00	49.00	48.00	48.00	48.00	48.00	47.00	47.00	46.00	-	-	-	-	-	-	-
Float	-	-	-	1,100	-	-	-	709	-	-	-	1,700	-	-	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2018Q4
Cashflow From Operations	28.1%	-24,442	-33,999	-28,176	-44,756	-34,507	-34,312	-38,575	-38,335	-32,676	-28,131	-30,841	-38,616	-25,840	-29,116	-19,166	-24,893	-	-	-
Share Based Compensation	-16.5%	9,098	10,893	10,105	8,538	7,353	7,430	7,414	5,006	4,792	2,864	3,937	5,852	6,268	13,908	683	580	-	-	-
Cashflow From Investing	-21.4%	23,425	29,805	27,153	2,643	-51,748	20,159	-1,316	-33,390	-16,418	-21,822	-97,460	-6,807	10,358	-31,882	6,312	19,159	-	-	-
Cashflow From Financing	709.9%	33,229	4,103	1,043	5,277	65,600	2,533	1,042	3,723	934	6,187	150,808	2,218	-873	259,758	27.00	126,770	-	-	-

OM Income Statement

2023-12-31

Statements of Operations - USD ($) $ in Thousands	12 Months Ended
Statements of Operations - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue:
Revenue	$ 130,376	$ 115,375	$ 102,602
Cost of revenue:
Cost of revenue	101,376	97,542	94,994
Gross profit	29,000	17,833	7,608
Operating expenses:
Research and development	57,307	48,855	36,741
Sales and marketing	96,232	89,482	65,070
General and administrative	45,231	40,515	36,316
Total operating expenses	198,770	178,852	138,127
Loss from operations	(169,770)	(161,019)	(130,519)
Interest income and other income, net	10,171	3,291	498
Interest expense	(12,675)	(3,566)	(1,715)
Loss on extinguishment of term loan	0	(1,367)	0
Loss before provision for income taxes	(172,274)	(162,661)	(131,736)
Provision for income taxes	523	295	199
Net loss	$ (172,797)	$ (162,956)	$ (131,935)
Net loss per share, basic	$ (3.48)	$ (3.38)	$ (2.89)
Net loss per share, diluted	$ (3.48)	$ (3.38)	$ (2.89)
Shares used in computing net loss per share, basic	49,588	48,161	45,589
Shares used in computing net loss per share, diluted	49,588	48,161	45,589
Product Revenue
Revenue:
Revenue	$ 103,537	$ 93,388	$ 84,312
Cost of revenue:
Cost of revenue	74,454	82,510	84,639
Service and Other Revenue
Revenue:
Revenue	26,839	21,987	18,290
Cost of revenue:
Cost of revenue	$ 26,922	$ 15,032	$ 10,355

OM Balance Sheet

2023-12-31

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 68,509	$ 73,222
Short-term investments	134,815	214,280
Accounts receivable, net	32,980	28,070
Inventories	49,215	51,476
Prepaid expenses and other current assets	5,700	6,597
Total current assets	291,219	373,645
Restricted cash	3,329	3,311
Property and equipment, net	13,273	15,876
Operating lease right-of-use assets	5,375	6,117
Other assets	605	1,166
Total assets	313,801	400,115
Current liabilities:
Accounts payable	5,827	603
Accrued compensation and related benefits	19,005	21,519
Accrued expenses and other current liabilities	13,459	16,227
Accrued warranty liability	3,712	3,620
Deferred revenue, current	11,727	8,662
Operating lease liabilities, current	1,593	1,318
Total current liabilities	55,323	51,949
Accrued interest	896	113
Deferred revenue	101	151
Operating lease liabilities, noncurrent	4,482	5,576
Term loan	130,113	96,336
Total liabilities	190,915	154,125
Commitments and contingencies (Note 6)
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000 shares authorized, and no shares issued and outstanding as of December 31, 2023 and 2022	0	0
Common stock, $0.001 par value; 300,000 shares authorized as of December 31, 2023 and 2022; 50,317 and 48,465 shares issued and outstanding as of December 31, 2023 and 2022, respectively	50	48
Additional paid-in capital	1,084,515	1,035,456
Accumulated other comprehensive loss	68	(564)
Accumulated deficit	(961,747)	(788,950)
Total stockholders' equity	122,886	245,990
Total liabilities and stockholders' equity	$ 313,801	$ 400,115

About Outset Medical Inc

Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. It provides the Tablo Hemodialysis System, which comprises a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.

CEO	Ms. Leslie L. Trigg
WEBSITE	outsetmedical.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	518

Outset Medical Inc Frequently Asked Questions

What is the ticker symbol for Outset Medical Inc? What does OM stand for in stocks?

OM is the stock ticker symbol of Outset Medical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Outset Medical Inc (OM)?

As of Tue Apr 23 2024, market cap of Outset Medical Inc is 124.24 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OM stock?

You can check OM's fair value in chart for subscribers.

What is the fair value of OM stock?

You can check OM's fair value in chart for subscribers. The fair value of Outset Medical Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Outset Medical Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for OM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Outset Medical Inc a good stock to buy?

The fair value guage provides a quick view whether OM is over valued or under valued. Whether Outset Medical Inc is cheap or expensive depends on the assumptions which impact Outset Medical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OM.

What is Outset Medical Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, OM's PE ratio (Price to Earnings) is -0.72 and Price to Sales (PS) ratio is 0.95. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OM PE ratio will change depending on the future growth rate expectations of investors.